

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/675,294	09/30/2003	Richard L. Mueller JR.	ACU-127	5446
7590 01/04/2007		EXAMINER STEPHENS, JACQUELINE F		
OLSON & HIERL, LTD. 36th Floor				
20 North Wacker Drive Chicago, IL 60606			ART UNIT	PAPER NUMBER
			3761	3761
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		01/04/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		μ				
		Application No.	Applicant(s)			
Office Action Summary		10/675,294	MUELLER, RICHARD L.			
		Examiner	Art Unit			
		Jacqueline F. Stephens	3761			
Period fo	The MAILING DATE of this communication ap or Reply	opears on the cover sheet with	the correspondence address			
VVHI( - Exte after - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR REP CHEVER IS LONGER, FROM THE MAILING I insions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory periouse are to reply within the set or extended period for reply will, by status reply received by the Office later than three months after the mail and patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC, .136(a). In no event, however, may a repd will apply and will expire SIX (6) MONTI	ATION.  lly be timely filed  HS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on		•			
2a) <u></u>	This action is <b>FINAL</b> . 2b) This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is					
	closed in accordance with the practice under	Ex parte Quayle, 1935 C.D.	11, 453 O.G. 213.			
Disposit	ion of Claims					
4)⊠ Claim(s) <u>1-48</u> is/are pending in the application.						
•	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)	Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>1-48</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)	Claim(s) are subject to restriction and	or election requirement.				
Applicat	ion Papers					
9)[	The specification is objected to by the Examir	ner.				
10)	The drawing(s) filed on is/are: a) ac	ccepted or b) objected to b	y the Examiner.			
	Applicant may not request that any objection to th					
40	Replacement drawing sheet(s) including the corre	,				
11)[	The oath or declaration is objected to by the B	Examiner. Note the attached	Office Action or form P1O-152.			
<b>Priority</b>	under 35 U.S.C. § 119					
12)	Acknowledgment is made of a claim for foreig	n priority under 35 U.S.C. §	119(a)-(d) or (f).			
a)	☐ All b)☐ Some * c)☐ None of:					
	1. Certified copies of the priority documer					
	2. Certified copies of the priority documer	•	·			
	3. Copies of the certified copies of the pri application from the International Bure	·	eceived in this National Stage			
* (	See the attached detailed Office action for a lis	, , , , , , , , , , , , , , , , , , , ,	eceived.			
			,			
Attachmer	it(s)					
	ce of References Cited (PTO-892)	4) Interview Su				
	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08)		/Mail Date ormal Patent Application			
	er No(s)/Mail Date	6) Other:	• •			
S. Patent and	Frademark Office	· · · · · · · · · · · · · · · · · · ·				

## **DETAILED ACTION**

## Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

2. Claims 1-4, 6, 9, 12, 21-24, 26, 27, 30, 33, and 42-48 are rejected under 35 U.S.C. 102(e) as being anticipated by Hung et al. US Patent Application Publication 20040249317. Hung discloses a kit including a catheter, syringe, nipple orifice dilator, harness, instructions, and method for reducing systemic losses in ductal lavage procedure comprising a base member a through aperture sized to receive a human breast therethrough; and a breast stabilizer 1integral with the base member and

Art Unit: 3761

surrounding the through aperture (Figure 3; paragraphs 0022-0025, 0037, and 0044-0050).

Page 3

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- Claims 1-48 are rejected under 35 U.S.C. 102(e) as being anticipated by 3. Kermode et al. US 6846218

The applied reference has a common assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another." or by an appropriate showing under 37 CFR 1.131.

As to claims 1, 21, and 42-48, Kermode discloses a kit including a catheter, 4. syringe, nipple orifice dilator, harness, instructions, and method for reducing systemic losses in ductal lavage procedure comprising a base member 16, a through aperture 12 sized to receive a human breast therethrough; and a breast stabilizer 15 integral with the base member and surrounding the through aperture (Figures 1 and 2; col. 6, lines 19-47)

As to claims 2 and 22, and the base member 16 comprises a torso band 10 having first and second end portions.

As to claims 3-5 and 23-25, the first and second end portions are engageable with each other (Figures 1 and 2).

As to claims 6, 26, and 27, the breast stabilizer is unitary with the base member (Figure 1).

As to claims 7 and 28 the breast stabilizer is made from an elastomeric material (col. 4, lines 64-67).

As to claims 8 and 29 the circumference of the breast stabilizer is adjustable (col. 5, lines 1-33).

As to claims 9 and 30 limitation is relative to the size of the breast base diameter.

With a larger breast, the aperture is smaller than the breast base diameter.

As to claims 10 and 31 the base member 16 further includes an elongated slit 14.

Art Unit: 3761

As to claims 11 and 32 the base member further includes a cover over the slit (col. 6, lines 26-32).

As to claims 12-16 and 33-37 see col. 4, lines 47-51 and col. 5, lines 1-33.

As to claims 17 and 38 see Figure 1, through aperture 12 and slot 14.

As to claims 18-20 and 40-42 see col. 7, lines 2-18.

## Double Patenting

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 1-48 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 6846218.

Application/Control Number: 10/675,294

Art Unit: 3761

Page 6

Although the conflicting claims are not identical, they are not patentably distinct from each other because the present application claims a generic breast stabilizer. The '218 patent specifically claims a breast elevating module and a breast stabilizing ring, which obviously includes a breast stabilizer in that the breast elevating module and breast stabilizing ring operate to maintain a human breast in a suitable stable position for performing a surgical procedure on the breast.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacqueline F. Stephens whose telephone number is (571) 272-4937. The examiner can normally be reached on Monday-Friday 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on (571) 272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3761

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Primary Examiner Art Unit 3761

December 21, 2006